Immunocan Raises ¥250M for AI Antibody Discovery

Shanghai-based Immunocan has successfully concluded a substantial Series A funding round, raising ¥250 million (approximately $34.5 million USD). This significant capital infusion was spearheaded by Vivo Capital, with crucial participation from Gold Mine Multi Family Office. Existing backers, including Kingray Capital and TigerYeah Capital, also demonstrated continued confidence through follow-on investments.

The newly acquired funds are earmarked for several strategic initiatives designed to accelerate Immunocan's growth and technological advancement. A primary focus will be on enhancing its proprietary gene-edited animal platforms, a critical component for generating diverse and high-affinity antibody candidates. Furthermore, the company plans to advance the commercialization of its innovative fully human antibody rabbit platform, a key differentiator in the competitive biopharmaceutical discovery space.

Immunocan is also prioritizing the development of an advanced AI-driven antibody drug screening platform. This integration of artificial intelligence is expected to dramatically improve the speed and efficiency of identifying promising therapeutic antibodies, a significant bottleneck in traditional drug development. The company also intends to expand its scientific and operational teams to support these ambitious goals.

Established in 2020, Immunocan has rapidly built a robust, multi-species antibody discovery ecosystem. Its platform portfolio encompasses established models such as mice and alpacas, alongside its specialized rabbit models. This comprehensive approach allows for tailored discovery campaigns to meet diverse therapeutic needs. The company's MabAI platform further underscores its commitment to leveraging cutting-edge technology for antibody generation and characterization.

The antibody therapeutics market is experiencing robust expansion, driven by increasing demand for targeted treatments for complex diseases like cancer and autoimmune disorders. Global spending on antibody-based drugs is projected to surpass hundreds of billions of dollars in the coming years. Immunocan's focus on innovative platforms positions it to capture a significant share of this dynamic market, addressing the industry's need for faster, more efficient discovery pipelines.

Immunocan's strategic partnerships with numerous domestic and international pharmaceutical firms, including several leading global drugmakers, highlight the market's validation of its technology. These collaborations are instrumental in translating Immunocan's platform capabilities into tangible drug development programs, demonstrating the real-world applicability and commercial potential of its discovery engine.